Nicox Ophthalmics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2007-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.nicox.com
Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution
Phase 2
Recruiting
- Conditions
- Open Angle Glaucoma
- Interventions
- Drug: PlaceboDrug: NCX 470
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Nicox Ophthalmics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05938699
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis
Phase 2
Completed
- Conditions
- Blepharitis
- Interventions
- Drug: NCX 4251Drug: Placebo
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Nicox Ophthalmics, Inc.
- Target Recruit Count
- 224
- Registration Number
- NCT04675242
- Locations
- 🇺🇸
Eye Research Foundation, Newport Beach, California, United States
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Phase 3
Active, not recruiting
- Conditions
- Open Angle GlaucomaOcular Hypertension
- Interventions
- Drug: NCX 470 0.1%Drug: Latanoprost 0.005%
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Nicox Ophthalmics, Inc.
- Target Recruit Count
- 696
- Registration Number
- NCT04630808
- Locations
- 🇨🇳
Nicox Clinical Site, Tianjing, China
Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- Open Angle GlaucomaOcular Hypertension
- Interventions
- Drug: NCX 470 0.1% (initial phase of trial)Drug: Latanoprost 0.005% (remainder of trial)Drug: Latanoprost 0.005% (initial phase of trial)Drug: NCX 470 0.1% (remainder of trial)Drug: NCX 470 0.065% (initial phase of trial)
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Nicox Ophthalmics, Inc.
- Target Recruit Count
- 670
- Registration Number
- NCT04445519
- Locations
- 🇺🇸
Eye Research Foundation, Newport Beach, California, United States
Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Nicox Ophthalmics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03926026
- Locations
- 🇺🇸
Texan Eye, Austin, Texas, United States
Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Phase 2
Completed
- Conditions
- Glaucoma, Open-AngleHypertension, Ocular
- Interventions
- Drug: NCX 470Drug: Latanoprost 0.005%
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Nicox Ophthalmics, Inc.
- Target Recruit Count
- 656
- Registration Number
- NCT03657797
- Locations
- 🇺🇸
Texan Eye, Austin, Texas, United States
A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution
Phase 3
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: AC-170 0.24%Drug: AC-170 Vehicle
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Nicox Ophthalmics, Inc.
- Target Recruit Count
- 516
- Registration Number
- NCT02756624
- Locations
- 🇺🇸
Ora Clinical Site Network, Andover, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath